Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings results on Thursday. The company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02, Morningstar.com reports. The company had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $0.66 million. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%.
Shares of EYPT stock traded up $0.02 during trading hours on Friday, reaching $2.48. The company had a trading volume of 1,160 shares, compared to its average volume of 326,682. Eyepoint Pharmaceuticals has a one year low of $1.05 and a one year high of $3.94. The firm has a market capitalization of $233.34 million, a PE ratio of -4.24 and a beta of 2.01. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.37.
A number of equities analysts have recently commented on EYPT shares. ValuEngine raised shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Thursday, February 7th. Finally, HC Wainwright set a $5.00 price objective on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 4th.
Several hedge funds have recently made changes to their positions in EYPT. Northern Trust Corp purchased a new position in Eyepoint Pharmaceuticals during the second quarter valued at approximately $218,000. BlackRock Inc. purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at $304,000. California Public Employees Retirement System purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter valued at $135,000. Vanguard Group Inc lifted its position in shares of Eyepoint Pharmaceuticals by 2.7% in the third quarter. Vanguard Group Inc now owns 1,798,708 shares of the company’s stock valued at $6,422,000 after acquiring an additional 47,361 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the third quarter valued at $134,000. Hedge funds and other institutional investors own 57.99% of the company’s stock.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.
Recommended Story: Preferred Stock
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.